{"id":"vancomycin-1-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"2-5%","effect":"Anemia"},{"rate":"2-5%","effect":"Thrombocytopenia"},{"rate":"1-2%","effect":"Renal impairment"},{"rate":"1-2%","effect":"Hypokalemia"},{"rate":"1-2%","effect":"Hypomagnesemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This prevents the incorporation of these precursors into the bacterial cell wall, ultimately leading to cell lysis and death. Vancomycin has a high affinity for the bacterial cell wall and is able to inhibit cell wall synthesis even at low concentrations.","oneSentence":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:22.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of serious or severe bacterial infections caused by susceptible strains of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and other susceptible Gram-positive bacteria."}]},"trialDetails":[{"nctId":"NCT02432807","phase":"PHASE3","title":"Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Kurobe LLC","startDate":"2015-05","conditions":"Bacterial Conjunctivitis","enrollment":303}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":437,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vancomycin 1.1%","genericName":"Vancomycin 1.1%","companyName":"Kurobe LLC","companyId":"kurobe-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors. Used for Treatment of serious or severe bacterial infections caused by susceptible strains of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and other susceptible Gram-positive bacteria..","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}